CWW partners occupy top two positions in prestigious Access to Medicine Index rankings: GSK retains 1st position for 5th consecutive time & J&J climbs to 2nd place
GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) are first and second overall in the Access to Medicine Index (ATMI), which ranks the degree to which pharmaceutical companies have made their medicines accessible to people in low and middle-income countries. The biennial ranking was announced on November 14 by the Access to Medicine Foundation, which published its first such ranking in 2008.
“The ranking provides the big picture – which company is best, overall, at mobilizing to reach the poor”, said Jayasree K. Iyer, executive director of the Access to Medicine Foundation. GSK retained its top position for the 5th consecutive time, and J&J climbed to 2nd place, a one-spot improvement from the last ranking.
In a press statement, GSK said it achieved its first place ranking for the fifth consecutive time by taking a “leadership position in research & development; pricing, manufacturing and distribution of medicines; and product donations.” Overall, GSK achieved an improved score compared to the 2014 Index and was ranked among top three in all but one of seven categories. The 2016 Index described GSK as “the most access-oriented company”.
“We are delighted that our commitments to widening access to the most possible patients have been recognised by the Access to Medicines Index for almost a decade,” said GSK CEO Sir Andrew Witty. “We have made fundamental changes to our business model so that it is founded on both innovation and access. But we cannot stand still.” Sir Andrew added that as a business, and an industry, they must push themselves to go further and faster in strengthening access to healthcare. GSK is a long-time partner and supporter of Children Without Worms (CWW).
In its most detailed review yet of company performance, the ATMI noted that Johnson & Johnson rose to second place, with leading approaches in several categories. “[J&J’s] strong performance is driven by a broad access strategy, with a clear direction for its long-term access program in Africa,” the report card noted.
J&J has established a new Global Public Health unit to address disease-specific global health problems. “The company demonstrates deepened commitment through the establishment of its global public health strategy, which links product development, manufacturing, distribution and capacity building.”
In 2005, J&J and the Task Force for Global Health jointly founded CWW. Through its new Global Public Health unit, J&J continues its strong support of CWW. GSK joined the STH campaign in 2012 with its donation of albendazole. Collectively, the companies have pledged 600 million STH treatments annually. The World Health Organization manages donated STH drugs on behalf of the two companies. Both J&J and GSK are also founding members of the STH Coalition, which facilitates collaborative action among 60 member organizations involved in various facets of STH control.
Children Without Worms is proud to acknowledge the humanitarian efforts of our two core partners. Their contribution to global STH control is one facet of two dynamic companies which have both made immense contributions to global public health.
 GLAXOSMITHKLINE, GSK and the GSK Logo are trademarks of the GSK group of companies and are used with the permission of GSK.